Skip to main content

Table 2 Clinical and biochemical parameters within the groups

From: Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial

  Linagliptin Group Voglibose Group Control Group
Parameters Baseline
(n = 10)
6 months
(n = 10)
P value Baseline
(n = 9)
6 months
(n = 9)
P value Baseline
(n = 7)
6 months
(n = 7)
P value
Weight (Kg) 75.3 (69.2–85.3) 73.4(66.3–84.3) 0.066 60.7(55.4–71.5) 56.8(53.5–67.7) 0.208 74.0(58.7–84.4) 75.3(57.9–82.4) 0.612
BMI (kg/m2) 25.5 (23.6–31.1) 25.0(23.1–30.1) 0.093 25.9(23.8–26.6) 24.4(23.8–25.7) 0.260 26.4(23.8–30.5) 26.6(23.7–30.7) 0.612
HbA1c (%) 6.8 (6.4–7.1) 6.6 (6.3–6.9) 0.474 7.0(6.8–7.4) 6.6 (6.5–6.6) 0.015a 7.0(6.8–7.1) 7.0(6.8–7.4) 0.491
Fasting Plasma Glucose (mmol/L) 6.5(5.9–7.3) 6.3(5.6–6.9) 0.308 6.9(6.2–7.4) 6.3(5.8–6.6) 0.058 6.2(6.1–6.6) 6.9(6.2–7.4) 0.310
HOMA-IR 2.0(1.9–2.3) 1.7(1.1–2.1) 0.169 1.6(1.3–2.0) 1.7(1.2–1.9) 0.678 2.4(1.7–3.3) 0.128 0.128
HOMA-β (%) 84.1(75.1–95.9) 81.9(70.8–90.2) 0.285 65.0(52.2–85.7) 78.3(59.9–111.6) 0.374 81.2(69.7–134.8) 0.866 0.866
Mixed Meal Tolerance Test
 AUC C-peptide (nmol/L) 473.3(376.9–567.8) 364.2(301.2–483.1) 0.508 421.2(40.9.8–526.9) 337.6(328.9–353.9) 0.139 595.6(460.5–623.8) 570.6(344.6–697.2) 1.000
 M0 ×10−8 (1/min) − 0.4(− 2.6–0.8) 2.1(− 0.6–3.3) 0.203 −0.5 (− 2.8–1.2) 2.9(0.5–3.2) 0.214 − 2.6(− 5.9–1.2) 0.1(− 3.7–4.3) 0.176
 M1 × 10− 8 (1/min) 6.4(4.5–8.7) 4.6(3.1–5.2) 0.333 5.7(3.6–7.6) 3.3(2.4–4.2) 0.214 7.7(5.5–1.2) 3.8(1.6–8.3) 0.310
Hyperinsulinemic-Euglycemic Clamp Study
 Glucose disposal rate (mg/Kg min) 2.7(2.0–5.5) 2.9(2.7–3.9) 0.508 3.2(2.6–3.5) 3.4(3.1–3.8) 0.173 2.2(1.8–3.0) 2.6(1.8–3.0) 0.866
 Insulin sensitivity (mg/(Kgmin)/μU/mL) 4.4(2.5–8.0) 4.0(3.4–5.9) 0.878 5.3(3.6–6.7) 5.6(5.2–6.1) 0.859 3.2(2.3–5.1) 3.4(2.4–4.8) 0.866
  1. All values are expressed as median and interquartile range (1st IQR – 3rd IQR)
  2. AUC Area under curve, M0 Basal β-cell function, M1 postprandial β-cell function, HOMA-IR Homeostatic model assessment of insulin resistance, and HOMA-β Homeostatic model assessment of β cell function
  3. aSignificant difference from baseline